{"id":46069,"date":"2025-11-07T13:26:38","date_gmt":"2025-11-07T05:26:38","guid":{"rendered":"https:\/\/flcube.com\/?p=46069"},"modified":"2025-11-07T13:26:38","modified_gmt":"2025-11-07T05:26:38","slug":"cstone-pharmaceuticals-to-unveil-cs2015-data-at-2025-acaai-meeting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46069","title":{"rendered":"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting"},"content":{"rendered":"\n<p>China\u2011based <strong>CStone Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2616:HKG\">HKG: 2616<\/a>) announced that the pre\u2011clinical results for its bispecific biologic <strong>CS2015<\/strong> will be presented at the <strong>2025 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting<\/strong> in Boston. The data will focus on the molecule\u2019s dual\u2011target mechanism against <strong>OX40L<\/strong> and <strong>TSLP<\/strong>, two validated drivers of Type\u20112 inflammation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-cs2015\">What Is CS2015?<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Design:<\/strong> Asymmetric bispecific antibody engineered to bind <strong>OX40L<\/strong> (OX40 ligand) <strong>and<\/strong> <strong>TSLP<\/strong> (thymic stromal lymphopoietin) simultaneously.<\/li>\n\n\n\n<li><strong>Fc Engineering:<\/strong> Contains a mutated Fc region that <strong>reduces Fc\u03b3R binding<\/strong> and <strong>extends circulating half\u2011life<\/strong>, delivering a more favorable pharmacokinetic (PK) profile for <strong>extended dosing intervals<\/strong>.<\/li>\n\n\n\n<li><strong>Pre\u2011clinical efficacy:<\/strong> In an atopic dermatitis (AD) model using <strong>OX40\u2011 and TSLP\u2011humanized mice<\/strong>, CS2015 achieved <strong>robust disease control<\/strong>, markedly lowering skin inflammation scores compared with single\u2011target controls.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Target validation<\/strong><\/td><td>OX40L and TSLP are both clinically proven to drive the Type\u20112 immune axis, giving CS2015 a strong mechanistic rationale for AD, asthma and other allergic diseases.<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Dual\u2011target approach may overcome the limited efficacy seen with monotherapy antibodies that block only one pathway.<\/td><\/tr><tr><td><strong>Commercial potential<\/strong><\/td><td>If clinical translation mirrors pre\u2011clinical results, CS2015 could capture a sizable share of the <strong>$10\u202fbn global atopic dermatitis market<\/strong> and expand into broader Type\u20112 indications.<\/td><\/tr><tr><td><strong>Regulatory pathway<\/strong><\/td><td>CStone plans to file an IND in 2026, leveraging the ACAA\u200bI presentation to build scientific credibility with the FDA and global regulators.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-reaction\">Market Reaction<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CStone stock (2616.HK)<\/strong> rose <strong>2.1\u202f%<\/strong> in early trading following the announcement, reflecting investor optimism around the bispecific platform.<\/li>\n\n\n\n<li><strong>Analyst commentary:<\/strong> Several Hong\u2011Kong sell\u2011side analysts upgraded CStone to \u201cBuy,\u201d citing the <strong>dual\u2011target strategy<\/strong> as a differentiator in a crowded biologics landscape.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements regarding CStone Pharmaceuticals\u2019 development timeline, regulatory expectations and commercial prospects for CS2015. Actual results may differ due to risks and uncertainties described in the company\u2019s filings with the Hong\u202fKong Stock Exchange.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110700182_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025110700182_c.\"><\/object><a id=\"wp-block-file--media-cb21dda0-659e-4df0-a4c5-4e9c5d7bafa2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110700182_c.pdf\">2025110700182_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110700182_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cb21dda0-659e-4df0-a4c5-4e9c5d7bafa2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based CStone Pharmaceuticals (HKG: 2616) announced that the pre\u2011clinical results for its bispecific biologic CS2015&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46071,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,65,188,856],"class_list":["post-46069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-auto-immune","tag-cstone-pharmaceuticals","tag-hkg-2616"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based CStone Pharmaceuticals (HKG: 2616) announced that the pre\u2011clinical results for its bispecific biologic CS2015 will be presented at the 2025 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting in Boston. The data will focus on the molecule\u2019s dual\u2011target mechanism against OX40L and TSLP, two validated drivers of Type\u20112 inflammation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46069\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting\" \/>\n<meta property=\"og:description\" content=\"China\u2011based CStone Pharmaceuticals (HKG: 2616) announced that the pre\u2011clinical results for its bispecific biologic CS2015 will be presented at the 2025 American College of Allergy, Asthma &amp; Immunology (ACAAI) Annual Scientific Meeting in Boston. The data will focus on the molecule\u2019s dual\u2011target mechanism against OX40L and TSLP, two validated drivers of Type\u20112 inflammation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46069\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T05:26:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0706.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting\",\"datePublished\":\"2025-11-07T05:26:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0706.webp\",\"keywords\":[\"Academic conference\",\"Auto-immune\",\"CStone Pharmaceuticals\",\"HKG: 2616\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46069#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46069\",\"name\":\"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0706.webp\",\"datePublished\":\"2025-11-07T05:26:38+00:00\",\"description\":\"China\u2011based CStone Pharmaceuticals (HKG: 2616) announced that the pre\u2011clinical results for its bispecific biologic CS2015 will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston. The data will focus on the molecule\u2019s dual\u2011target mechanism against OX40L and TSLP, two validated drivers of Type\u20112 inflammation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46069\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0706.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0706.webp\",\"width\":1080,\"height\":608,\"caption\":\"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46069#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based CStone Pharmaceuticals (HKG: 2616) announced that the pre\u2011clinical results for its bispecific biologic CS2015 will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston. The data will focus on the molecule\u2019s dual\u2011target mechanism against OX40L and TSLP, two validated drivers of Type\u20112 inflammation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46069","og_locale":"en_US","og_type":"article","og_title":"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting","og_description":"China\u2011based CStone Pharmaceuticals (HKG: 2616) announced that the pre\u2011clinical results for its bispecific biologic CS2015 will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston. The data will focus on the molecule\u2019s dual\u2011target mechanism against OX40L and TSLP, two validated drivers of Type\u20112 inflammation.","og_url":"https:\/\/flcube.com\/?p=46069","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-07T05:26:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0706.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46069#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46069"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting","datePublished":"2025-11-07T05:26:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46069"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46069#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0706.webp","keywords":["Academic conference","Auto-immune","CStone Pharmaceuticals","HKG: 2616"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46069#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46069","url":"https:\/\/flcube.com\/?p=46069","name":"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46069#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46069#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0706.webp","datePublished":"2025-11-07T05:26:38+00:00","description":"China\u2011based CStone Pharmaceuticals (HKG: 2616) announced that the pre\u2011clinical results for its bispecific biologic CS2015 will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston. The data will focus on the molecule\u2019s dual\u2011target mechanism against OX40L and TSLP, two validated drivers of Type\u20112 inflammation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46069#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46069"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46069#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0706.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0706.webp","width":1080,"height":608,"caption":"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46069#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA\u200bI Meeting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0706.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46069"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46069\/revisions"}],"predecessor-version":[{"id":46072,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46069\/revisions\/46072"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46071"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}